Chunghwa Chemical Synthesis & Biotech Co., Ltd.
1762.TW
Price:
$24.95
Market Cap:
$1.92B
Chunghwa Chemical Synthesis & Biotech Co., Ltd. engages in the research, development, manufacture, and wholesale of active pharmaceutical ingredients (APIs) in Taiwan and the United States. It offers API products, which include immunosuppressant, oncology, cardiovascular, and other products, as well as peptide drugs. The company also develops bulk pharmaceutical products, such as anti-anxiety agents, antidiabetics, laxatives, antifungals, antihistamines, antiseptics, antiulcerants, cardiovascular drugs, skeletal, muscle relaxants, hypolipaemics, antineoplastic, antihyperlipedemias, and immunosuppressant products, as well as provides research and development, and contract manufacturing servic...[Read more]
Industry
Biotechnology
IPO Date
2010-12-20
Stock Exchange
TAI
Ticker
1762.TW
PE Ratio
[-15.69]
ROE
[-2.06%]
Current Ratio
[2.82]
Dividend Yield
[0.77%]
Enterprise Value
[2.56B]
Dividend History
The ROE as of December 2025 (TTM) for Chunghwa Chemical Synthesis & Biotech Co., Ltd. (1762.TW) is -2.06%
According to Chunghwa Chemical Synthesis & Biotech Co., Ltd.’s latest financial reports and current stock price. The company's current ROE is -2.06%. This represents a change of 290.85% compared to the average of -0.53% of the last 4 quarters.
Chunghwa Chemical Synthesis & Biotech Co., Ltd. (1762.TW) Historical ROE (quarterly & annually)
How has 1762.TW ROE performed in the past?
The mean historical ROE of Chunghwa Chemical Synthesis & Biotech Co., Ltd. over the last ten years is 10.17%. The current -2.06% ROE has changed -120.24% with respect to the historical average. Over the past ten years (40 quarters), 1762.TW's ROE was at its highest in in the June 2020 quarter at 15.62%. The ROE was at its lowest in in the June 2025 quarter at -2.07%.
Average
10.17%
Median
9.86%
Minimum
1.58%
Maximum
21.29%
Chunghwa Chemical Synthesis & Biotech Co., Ltd. (1762.TW) ROE by Quarter and Year
Discovering the peaks and valleys of Chunghwa Chemical Synthesis & Biotech Co., Ltd. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 1.71%
Maximum Annual ROE = 21.29%
Minimum Annual Increase = -80.02%
Minimum Annual ROE = 1.58%
| Year | ROE | Change |
|---|---|---|
| 2024 | 1.58% | -80.02% |
| 2023 | 7.91% | -45.81% |
| 2022 | 14.59% | 5.36% |
| 2021 | 13.85% | -34.95% |
| 2020 | 21.29% | 266.61% |
| 2019 | 5.81% | -50.83% |
| 2018 | 11.81% | 150.71% |
| 2017 | 4.71% | 38.37% |
| 2016 | 3.40% | -79.73% |
| 2015 | 16.80% | 1.71% |
Chunghwa Chemical Synthesis & Biotech Co., Ltd. (1762.TW) Average ROE
How has 1762.TW ROE performed in the past?
The current ROE of Chunghwa Chemical Synthesis & Biotech Co., Ltd. (1762.TW) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
8.03%
5-year avg
11.84%
10-year avg
10.17%
Chunghwa Chemical Synthesis & Biotech Co., Ltd. (1762.TW) ROE vs. Peers
How is 1762.TW’s ROE compared to its peers?
Chunghwa Chemical Synthesis & Biotech Co., Ltd.’s ROE is greater than Advagene Biopharma Co., Ltd. (-34.85%), greater than Genomics BioSci & Tech. Co.,Ltd. (-31.04%), greater than Sunny Pharmtech Inc. (-27.76%), less than Greenyn Biotechnology Co., Ltd (16.75%), greater than Meribank Biotech Co., Ltd (-5.56%), greater than Hcmed (-68.42%), greater than InnoPharmax Inc. (-18.51%), greater than Shangya Technology Co., Ltd. (-10.29%), greater than NaviFUS Corp. (-20.73%), greater than GlycoNex Incorporation (-19.51%),
| Company | ROE | Market cap |
|---|---|---|
| -34.85% | $1.74B | |
| -31.04% | $1.74B | |
| -27.76% | $2.10B | |
| 16.75% | $2.07B | |
| -5.56% | $1.67B | |
| -68.42% | $2.29B | |
| -18.51% | $2.28B | |
| -10.29% | $2.06B | |
| -20.73% | $1.47B | |
| -19.51% | $2.33B |
Build a custom stock screener for Chunghwa Chemical Synthesis & Biotech Co., Ltd. (1762.TW) and other stocks
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Chunghwa Chemical Synthesis & Biotech Co., Ltd. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
Chunghwa Chemical Synthesis & Biotech Co., Ltd. (1762.TW) and other stocks custom spreadsheet templates
The easiest way to analyze a company like Chunghwa Chemical Synthesis & Biotech Co., Ltd. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
Frequently asked questions❓
What is the ROE?
How can you use the ROE?
What is Chunghwa Chemical Synthesis & Biotech Co., Ltd.'s ROE?
How is the ROE calculated for Chunghwa Chemical Synthesis & Biotech Co., Ltd. (1762.TW)?
What is the highest ROE for Chunghwa Chemical Synthesis & Biotech Co., Ltd. (1762.TW)?
What is the 3-year average ROE for Chunghwa Chemical Synthesis & Biotech Co., Ltd. (1762.TW)?
What is the 5-year average ROE for Chunghwa Chemical Synthesis & Biotech Co., Ltd. (1762.TW)?
How does the current ROE for Chunghwa Chemical Synthesis & Biotech Co., Ltd. (1762.TW) compare to its historical average?